Prosecution Insights
Last updated: April 19, 2026
Application No. 18/250,738

5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER

Final Rejection §102
Filed
Apr 26, 2023
Examiner
REILLY, SOPHIA JANE
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Godavari Biorefineries Limited
OA Round
2 (Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
3y 6m
To Grant
99%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allow Rate
31 granted / 54 resolved
-2.6% vs TC avg
Strong +51% interview lift
Without
With
+51.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
36 currently pending
Career history
90
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
33.2%
-6.8% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
26.1%
-13.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 54 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application is a 371 National Stage Entry of PCT/IN2021/051015 filed on October 26, 2021 which claims priority to foreign application No. IN202021046675 filed on October 26, 2020. Status of Claims Acknowledgement is made of original (12), amended (1, 7, 9-10), previously presented (8, 11, 13), cancelled (2-6), and new (14-16) claims filed December 31, 2025. Claims 1, 7-16 are pending in instant application. Response to Arguments Applicant’s amendments filed December 31, 2025 have overcome the following: The objections to claims 1-7, The rejection of claims 1-7, 9-10 under 35 U.S.C. 112(b), The rejection of claims 9-10 under 35 U.S.C. 112(d), The rejection of claims 1, 5 under 35 U.S.C. 102(a)(1) as being anticipated by Wolf et. al.1, and The rejection of claims 1, 4, 8-13 under 35 U.S.C. 102(a)(1) as being anticipated by WO 2017/106624 A1 to Gao et. al.2 The above rejections/objects have thus been withdrawn. However, in light of claim amendments, a new rejection under 35 U.S.C. 102(a)(1) has been made. Claim Interpretation The phrase in claim 1 “Q is O or -Q-(CH2)n-R is absent” is understood to mean Q may be O, or H is present in lieu of the -Q-(CH2)n-R substituent. In addition, claim 1 states “when R = -COOH, n = 3 to 6” which is understood to mean when R is COOH, -Q-(CH2)n-R is present, and n is 3 to 6. New Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by STN3. STN teaches CAS Registry No. 130-15-4 which reads on instant Formula I when -Q-(CH2)n-R is absent, R1, R2, R3 are H, R4 is H, and R6 is H. CAS# 130-15-4 Instant Formula I PNG media_image1.png 150 188 media_image1.png Greyscale PNG media_image2.png 188 220 media_image2.png Greyscale Allowable Subject Matter Claim 7-16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claim 7-16 are objected to. Claim 1 is rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SOPHIA J REILLY whose telephone number is (703)756-5669. The examiner can normally be reached 9:00 am - 5:00 pm EST M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, KORTNEY KLINKEL can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /S.R./Examiner, Art Unit 1627 /JENNIFER A BERRIOS/ Primary Examiner, Art Unit 1613 1 Wolf et. al. "The effect of naphthalene and naphthoquinone derivatives on the activity of (alanine)-aminopeptidase from pig kidneys" Wissenschaftliche Zeitschrift Martin-Luther-Universitaet Halle-Wittenberg, Mathematisch-Naturwissenschaftliche Reihe 1977, 26, 1, 95-102. ISSN: 0138-1504. Hereinafter Wolf. 2 Published June 22, 2017. Hereinafter Gao. 3 CAS 130-15-4. CAS Registry File Accessed February 6, 2026 from STN, entered into STN November 16, 1984. Hereinafter STN.
Read full office action

Prosecution Timeline

Apr 26, 2023
Application Filed
Sep 25, 2025
Non-Final Rejection — §102
Dec 31, 2025
Response Filed
Feb 09, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600714
NEW PYRAZINE COMPOUND
2y 5m to grant Granted Apr 14, 2026
Patent 12589091
TOPICAL FORMULATION COMPRISING SIROLIMUS
2y 5m to grant Granted Mar 31, 2026
Patent 12570631
SUBSTITUTED N-(4-(PYRIMIDIN AND PYRIDIN-4-YL)BENZYLCARBOXAMIDES AND ITS USE FOR TREATING DISORDERS RESPONSIVE TO INHIBITION OF BTK
2y 5m to grant Granted Mar 10, 2026
Patent 12570638
Fused Imidazole Derivatives as AHR Antagonists
2y 5m to grant Granted Mar 10, 2026
Patent 12569495
INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
99%
With Interview (+51.1%)
3y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 54 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month